Nogapendekin Alfa
drugOn this page
Also known as Alt-803IL-15N72DN-803Nogapendekina alfaNogapendekine alfa
Summary
Nogapendekin Alfa (CHEMBL4297690) is a phase-3 clinical-stage protein; indicated across 33 conditions including non-small cell lung carcinoma and head and neck squamous cell carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 33 conditions
- Clinical trials: 72
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297690 |
| Name | Nogapendekin Alfa |
| Type | Protein |
| Max phase | 3 |
Also known as: Alt-803, ALT-803, IL-15N72D, N-803, Nogapendekin alfa, Nogapendekina alfa, Nogapendekine alfa, NOGAPENDEKIN ALFA
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
33 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| head and neck squamous cell carcinoma | 2 | MONDO:0010150 | EFO:0000181 |
| acute myeloid leukemia | 2 | MONDO:0018874 | EFO:0000222 |
| plasma cell myeloma | 2 | MONDO:0009693 | EFO:0001378 |
| exocrine pancreatic carcinoma | 2 | MONDO:0005192 | EFO:0002618 |
| urothelial carcinoma | 2 | MONDO:0040679 | EFO:0008528 |
| cutaneous neuroendocrine carcinoma | 2 | MONDO:0019210 | EFO:1001471 |
| myelodysplastic syndrome | 2 | MONDO:0018881 | EFO:0000198 |
| squamous cell carcinoma | 2 | MONDO:0005096 | EFO:0000707 |
| fallopian tube neoplasm | 2 | MONDO:0021092 | MONDO:0002158 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| ovarian cancer | 2 | MONDO:0008170 | MONDO:0008170 |
| colorectal adenocarcinoma | 2 | MONDO:0005008 | EFO:0000365 |
| AIDS | 2 | MONDO:0012268 | EFO:0000765 |
| malignant pancreatic neoplasm | 2 | MONDO:0009831 | EFO:1000359 |
| glioblastoma | 2 | MONDO:0018177 | EFO:0000519 |
| head and neck cancer | 2 | MONDO:0005627 | EFO:0006859 |
| colorectal neoplasm | 2 | MONDO:0005335 | MONDO:0005575 |
| metastatic prostate carcinoma | 1 | MONDO:0004956 | EFO:0000196 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| melanoma | 1 | MONDO:0005105 | EFO:0000756 |
| HIV infectious disease | 1 | MONDO:0005109 | EFO:0000764 |
| non-Hodgkin lymphoma | 1 | MONDO:0018908 | EFO:0005952 |
| hepatocellular carcinoma | 1 | MONDO:0007256 | EFO:0000182 |
| severe acute respiratory syndrome | 1 | MONDO:0005091 | MONDO:0100096 |
| chordoma | 1 | MONDO:0008978 | MONDO:0008978 |
| endometrial carcinoma | 1 | MONDO:0002447 | EFO:1001512 |
| renal cell adenocarcinoma | 0 | MONDO:0005549 | EFO:0005708 |
5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 72.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 29 |
| PHASE2 | 29 |
| PHASE1 | 10 |
| PHASE2/PHASE3 | 2 |
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03022825 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer |
| NCT05096663 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) |
| NCT06745908 | PHASE3 | RECRUITING | Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In |
| NCT02782546 | PHASE2 | ACTIVE_NOT_RECRUITING | Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation |
| NCT03228667 | PHASE2 | ACTIVE_NOT_RECRUITING | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors |
| NCT04390399 | PHASE2 | ACTIVE_NOT_RECRUITING | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer |
| NCT04505501 | PHASE2 | ACTIVE_NOT_RECRUITING | Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV Infection |
| NCT04847466 | PHASE2 | ACTIVE_NOT_RECRUITING | Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer |
| NCT05419011 | PHASE2 | ACTIVE_NOT_RECRUITING | Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome |
| NCT06061809 | PHASE2 | RECRUITING | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma |
| NCT06149481 | PHASE1/PHASE2 | RECRUITING | Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) |
| NCT06161545 | PHASE2 | RECRUITING | Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma |
| NCT06253494 | PHASE1/PHASE2 | RECRUITING | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer |
| NCT06710288 | PHASE2 | RECRUITING | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer |
| NCT06829823 | PHASE2 | NOT_YET_RECRUITING | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer |
| NCT07108036 | PHASE2 | RECRUITING | A Study to Assess Anktiva in Patients With Long Covid-19. |
| NCT07145164 | PHASE2 | ENROLLING_BY_INVITATION | Interleukin-15 to Promote Post-ART Control of HIV |
| NCT07477366 | PHASE2 | NOT_YET_RECRUITING | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma |
| NCT07574541 | PHASE2 | NOT_YET_RECRUITING | Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance |
| NCT01885897 | PHASE1/PHASE2 | COMPLETED | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT |
| NCT01898793 | PHASE1/PHASE2 | TERMINATED | Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
| NCT02384954 | PHASE1/PHASE2 | TERMINATED | QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab |
| NCT02465957 | PHASE2 | TERMINATED | QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) |
| NCT02523469 | PHASE1/PHASE2 | COMPLETED | ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT02989844 | PHASE2 | COMPLETED | Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT |
| NCT03003728 | PHASE2 | WITHDRAWN | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) |
| NCT03050216 | PHASE2 | COMPLETED | QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML |
| NCT03054909 | PHASE2 | COMPLETED | IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer |
| NCT03127098 | PHASE1/PHASE2 | TERMINATED | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer |
| NCT03136406 | PHASE1/PHASE2 | TERMINATED | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy |
| NCT03167164 | PHASE1/PHASE2 | WITHDRAWN | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy |
| NCT03167177 | PHASE1/PHASE2 | WITHDRAWN | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy |
| NCT03169738 | PHASE1/PHASE2 | WITHDRAWN | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors |
| NCT03169764 | PHASE1/PHASE2 | WITHDRAWN | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy |
| NCT03169777 | PHASE1/PHASE2 | WITHDRAWN | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC |
| NCT03169790 | PHASE1/PHASE2 | WITHDRAWN | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL |
| NCT03175666 | PHASE1/PHASE2 | WITHDRAWN | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy |
| NCT03197571 | PHASE1/PHASE2 | WITHDRAWN | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy |
| NCT03197584 | PHASE1/PHASE2 | WITHDRAWN | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy |
| NCT03329248 | PHASE1/PHASE2 | TERMINATED | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: non-small cell lung carcinoma